title: [A phase II trial of pirarubicin in untreated disseminated small cell lung cancer. A cooperative study of the French Pneumo-Cancerology Group].
abstract: The usual form of chemotherapy of metastatic small cell lung cancer gives a 50% objective response with a mean survival of 7-8 months. We have tested a new antimitotic drug using pirarubicin alone in 26 patients. After the second treatment we noticed a response level of 12% with moderate toxicity. Then, we undertook classical chemotherapy using cisplatin-V16. After 3 doses the response level was 50% with a median survival of 32 weeks. In our study the use of a single drug pirarubicin in metastatic small cell cancer did not appear to worsen the chance of survival in patients if polychemotherapy was carried out immediately in cases which failed on the single drug. Our monotherapy did not appear to induce resistance to affective polychemotherapy. This method applied carefully to patients with metastatic disease with a strict follow up may be utilised in the assessment of the efficacy of the newer antimitotic drugs.
authors.affiliation: Département des Maladies Respiratoires, Hôpital Sainte-Marguerite, Marseille.
authors.forename: J P
authors.initials: JP
authors.lastname: Kleisbauer
authors.forename: A
authors.initials: A
authors.lastname: Taytard
authors.forename: P
authors.initials: P
authors.lastname: Balmes
authors.forename: M
authors.initials: M
authors.lastname: Reynaud-Gaubert
authors.forename: J
authors.initials: J
authors.lastname: Vergeret
authors.forename: R
authors.initials: R
authors.lastname: Targhetta
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: F
authors.initials: F
authors.lastname: Bonnaud
authors.forename: R
authors.initials: R
authors.lastname: Poirier
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D005047:Etoposide; D004317:Doxorubicin; C027260:pirarubicin; D002945:Cisplatin
vernacular_title: Essai de phase II de la pirarubicine dans les cancers pulmonaires à petites cellules disséminés jamais traités. Etude Coopérative du Groupe Français de Pneumo-Cancérologie (GFPC).